Approved January 1998
Bristol-Myers Squibb received approval of its Excedrin Migraine for the treatment of pain associated with mild-to-moderate migraine. It is the first over the counter drug to be approved for this indication.
In trials involving about 1300 migraineurs, Excedrin Migraine was found safe and effective in relieving migraine pain within 2-to-4 hours of dosing.
Excedrin Migraine contains 250 mg acetaminophen, 250 mg aspirin, and 65 mg caffeine in each tablet. The ingredients are the same as those in Excedrin Extra, which is already on the market, but the product comes with instructions and warnings specific to migraine.
The Excedrin Migraine drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.